Nitrofurantoin Capsules
Failed Dissolution Specifications
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Failed dissolution specifications
Cause type: Dissolution failure
The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.
Nitrofurantoin Monohydrate/Macrycrystals Capsules, 100 mg, 100-count bottle, Rx Only, Distributed by: Alvogen, Inc. Pine Brook, NY 07058 USA, NDC 47781-303-01
Compare with the code on your package — it is the most precise check available.
Drug: Nitrofurantoin
From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.
| Product | Strength | Form & route | Labeler | Type |
|---|---|---|---|---|
| Nitrofurantoin Monohydrate/ Macrocrystalline Nitrofurantoin Monohydrate/Macrocrystalline NDC 47781-0303 |
NITROFURANTOIN 25 mg/1; NITROFURANTOIN MONOHYDRATE 75 mg/1 | Capsule Oral |
Alvogen Inc. | Rx |
Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.
Failed Dissolution Specifications
Failed Dissolution Specifications
Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Failed Dissolution Specifications
Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.
Sub-Potent Drug: Out of specification for assay at the 24 month interval.
Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.